Background: The existing analysis was performed to judge the impact of hotspot mutations on everolimus efficacy in BOLERO-2 participants, using cell-free DNA (cfDNA) from plasma samples collected during patient randomisation. happening in up to 45% of luminal A tumours (Tumor Genome Atlas Network, 2012); the majority is missense mutations clustering in the helical (and placebo… Continue reading Background: The existing analysis was performed to judge the impact of